The hospital will enhance its testing and
research of blood cancers with the SOPHiA DDM™ Platform
BOSTON and ROLLE, Switzerland, May 20, 2024
/PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native
healthcare technology company and a global leader in data-driven
medicine, today announced that Instituto Mário Penna is live on the
SOPHiA DDM™ Platform. Located in Belo
Horizonte, Brazil, the Instituto Mário Penna will
use SOPHiA GENETICS' technology to advance its testing,
research, and advance data-driven diagnoses and treatment decisions
for blood-related cancers and disorders.
Cancer is the second most common cause of death in Brazil, with 704,000 anticipated new cancer
cases expected between 2023 and 2025.1 On a global
scale, blood cancers are the fifth most common type of cancer in
the world.2 The Instituto Mário Penna specializes in
treating patients with cancer and is one of the largest providers
of oncology services in Brazil.
With 58 beds, the center offers both in-patient and out-patient
care, chemotherapy and radiation treatments, clinical laboratory
analysis, and surgical care. Instituto Mário Penna has implemented
the SOPHiA DDM™ Platform to improve its onsite testing capabilities
and to inform more data-driven treatment plans.
"At SOPHiA GENETICS we are committed to accelerating and
expanding the use of precision medicine," said Ricardo Mendonca Filho, PhD., Managing Director,
LAPAC, SOPHiA GENETICS. "Instituto Mário Penna is a staple within
the cancer-care community in Brazil, and its implementation of the SOPHiA
DDM™ Platform shows its commitment to advancing cancer care. We are
confident that our AI-based platform will help Instituto Mário
Penna generate fast, accurate, and meaningful insights to
support researchers and clinicians in making data-driven
decisions."
Advances in diagnostics and treatment of blood cancers depend on
timely, cost-effective, and reliable sequencing data. The SOPHiA
DDM™ Platform uses NGS to target key variants from FFPE, blood, or
bone marrow samples helping lead to fast and accurate detection of
variants associated with the disease.
The SOPHiA DDM™ Platform is specifically designed to compute a
wide array of genomic variants and continually hones its machine
learning algorithms to detect genomic variants associated with rare
and challenging cases. Additionally, the SOPHiA DDM™ Platform
delivers results that are nearly 100 percent reproducible to
provide consistent inter- and intra-run results, ensuring stable
and trustworthy sequencing data.
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect on LinkedIn.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare
technology company on a mission to expand access to data-driven
medicine by using AI to deliver world-class care to patients with
cancer and rare disorders across the globe. It is the creator
of the SOPHiA DDM™ Platform, which analyzes complex genomic
and multimodal data and generates real-time, actionable insights
for a broad global network of hospital, laboratory, and biopharma
institutions. For more information,
visit SOPHiAGENETICS.COM and connect with us
on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures, unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to
obtain the appropriate product information for your country of
residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains statements
that constitute forward-looking statements. All statements other
than statements of historical facts contained in this press
release, including statements regarding our future results of
operations and financial position, business strategy, products, and
technology, as well as plans and objectives of management for
future operations, are forward-looking statements. Forward-looking
statements are based on our management's beliefs and assumptions
and on information currently available to our management. Such
statements are subject to risks and uncertainties, and actual
results may differ materially from those expressed or implied in
the forward-looking statements due to various factors, including
those described in our filings with the U.S. Securities and
Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
1
https://www.cancer.net/blog/2023-07/cancer-my-community-addressing-health-disparities-brazil
2
https://www.worldwidecancerresearch.org/news-opinion/2022/september/blood-cancer-everything-you-need-to-know/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-announces-instituto-mario-penna-as-new-customer-302149227.html
SOURCE SOPHiA GENETICS